They were not on the White House podium for the Coronavirus Task Force briefings or on Twitter making breathless predictions about COVID-19.
But the senior leaders overseeing the US Food and Drug Administration’s review centers and their medical teams are demonstrating the value of quiet, effective leadership during a health crisis the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?